Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Patent
1995-02-22
1999-12-14
Campell, Bruce R.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
435 691, 4353201, 435325, 514 44, A01N 6300
Patent
active
060013494
ABSTRACT:
We have discovered that by using a recombinant DNA viral vector, preferably a pox virus vector having at least one insertion site containing a DNA segment encoding the carcinoma self-associated antigen, or a cytotoxic T-cell eliciting epitope thereof, operably linked to a promoter capable of expression in the host, human cytotoxic T-cells specific for the carcinoma self-associated antigens can be produced. The method preferably comprises introducing a sufficient amount of the recombinant pox virus vector into a host to stimulate production of cytotoxic T-cells, and contacting the host with additional antigen at periodic intervals thereafter. The additional antigen may be added by using a second pox virus vector from a different pox genus. In another embodiment, additional antigen is added by contacting the host with antigen. The antigen may be formulated with an adjuvant or in a liposomal formulation. The T-cells can be isolated. The number of T-cells can be expanded by contacting the isolated cytotoxic T-cells alternately with the carcinoma self-associated antigen or an epitope thereof and IL-2. The isolated T-cells can be used in a method for treating a host having a tumor expressing a carcinoma self-associated antigen comprising introducing cytotoxic T-cells specific for the antigen to the host and at at least one periodic interval thereafter introducing to the host a T-cell eliciting epitope of the carcinoma self-associated antigen.
REFERENCES:
patent: 5833975 (1998-11-01), Paoletti et al.
Schlom, et al., Aids Research and Human Retroviruses, vol. 10,No. S1, p. S58, Abstract (1994).
Salgaller, et al., Cancer Research, vol. 53, pp. 2154-2161 (1993).
Falk, et al., Nature, vol. 351, pp. 290-296 (1991).
Schlom, et al., Breast Cancer Research and Treatment, vol. 38, No. 1, pp. 27-39 (1996).
Tsang, et al., J. of Nat'l Cancer Inst., Vo. 87, No. 13, pp. 982-990 (1995).
Tsang, et al., Proceedings of the American Association for Cancer Research, vol. 36, p. 249, Abstract #1483 (1995).
Mitchel, J. of Nat'l Cancer Inst., vol. 87, No. 13, pp. 949-951 (1995).
Ngo et al., The protein folding problem and tertiary structure function Birkhauser Boston Inc., 14, 491-495, 1994.
Tannock et al. The basic Science of Oncology. McGraw-Hill, Inc. 1992:238-248.
Mastrangelo et al. Seminars in Oncology. 1996, vol. 23, No. 1:4-21.
Hwu. PPO Updates. 1995, vol. 9, No. 4:1-13.
Bei et al. J. Immunotherapy. 1994, 16:275-282.
Kent et al. AIDS Res. Hum. Retroviruses. 1994, vol. 10, No.5:551-60.
Oesterling, J.E., J. Urol. 145: 907-923, (1991).
Peace, D.J., et al.Cancer Vaccine Symposium. Cancer Research Institute. Oct. 3-5 (1994).
Fisk, B., et al. Int.J.Oncology 5: 51-63 (1994).
Ioannides, C.G., et al. J.Immunol 151: 3693-3703, (1993).
Tsang, K.Y., et al. Vaccine Research (in press).
Jung, S., et al. J.Exp.Med. 173: 273-276 (1991).
Fenton, S., et al. J.Natl. Cancer Inst. 85: 1294-1302, (1993).
Houblers, J.G.A., et al. Eur.J.Immunol. 23: 2072-2077, (1993).
Kantor, J., et al., J.Natl.Cancer Inst. 84: 1084-1091, (1992).
Kantor, J., et al. Cancer Res. 52: 6917-6925, (1992).
Mavligit, G.M., et al. Cancer (Phila) 52: 146-149, (1983).
Collatz, B., et al. Int.J.Cancer 8: 298-303, (1971).
Chester, K.A., et al. Clin.Exp.Immunol. 58: 685-693 (1984).
Ura, Y., et al. Cancer Lett. 24: 283-295, (1985).
Staab, et al. Br. J. Cancer 42:26 (1980).
Kantor, et al., Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. Journal of the National Cancer Institute 84:1084-1091; 1992.
Kantor, et al., Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Research 52:6917-6925; 1992.
Schlom, et al., Recombinant vaccines for the active specific immunotherapy of human cancer. Aids Research and Human Retroviruses 10(s1):S58; 1994.
Salgaller, et al., Baculovirus recombinants expressing the human carcinoembryonic antigen gene. Cancer Research 53:2154-2161; 1993.
Falk, et al., Allele specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351:290-296, 1991.
Schlom, et al., Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Research and Treatment 38:27-39; 1996.
Tsang, et al., Generation human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-Cea vaccine. Journal of the National Cancer Institute 87(13):982-900; 1995.
Tsang, et al., A recombinant CEA-vaccinia vaccine induces a CEA-specific cytotoxic T-cell response in carcinoma patinets. 36:249, 1995.
Mitchell, T cell mediated immunity to carcinoembryonic antigen in humans: An example of `swimming upstream`? Journal of the National Cancer Institute 87(13):949-951; 1995.
Panicali Dennis L.
Schlom Jeffrey
Campell Bruce R.
Eisenstein Ronald I.
Nguyen Dave Trong
Resnick David S.
The United States of America as represented by the Department of
LandOfFree
Generation of human cytotoxic T-cells specific for carcinoma sel does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Generation of human cytotoxic T-cells specific for carcinoma sel, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Generation of human cytotoxic T-cells specific for carcinoma sel will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-860438